Xintela Board recommends Lars Hedbys as new Board memberLund, Sweden, 12 November 2020 -Xintela AB (publ) announces that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings. Lars Hedbys (born 1957) has significant experience from leading positions and Board roles in the pharmaceutical, biotech and medtech industries with several senior positions in AstraZeneca, including Site General Manager, AstraZeneca R&D, Lund. He currently has several Board assignments including Chairman of the Board of Scandinavian ChemoTech AB (listed) and IAmPatient AB, and member of the Boards of RhoVac AB (listed), Cell Invent AB and Vetiqure AB. Among previous assignments are CEO of Idogen AB (listed), acting CEO of Pharmiva AB and Chairman of the Board of Lund Life Science Incubator AB.
Lars Hedbys has a M.Sc. in Chemical Engineering from Chalmers University of Technology and a Ph.D. in Applied Biochemistry from Lund Institute of Technology.
"I am delighted that Lars Hedbys has agreed to join our Board. He will contribute strongly to support our development and governance in this key stage of Xintela's growth. His knowledge, experience, judgement and network of contacts will be of great value as we move closer to clinical studies and commercialization", says Xintela's Chairman of the Board Gregory Batcheller.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].
The following documents can be retrieved from beQuoted
2020-11-12-Lars-Hedby ENG.pdf
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 